Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 26 09:40AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.90 Insider Own21.00% Shs Outstand78.34M Perf Week10.92%
Market Cap445.75M Forward P/E- EPS next Y-1.83 Insider Trans1.91% Shs Float61.70M Perf Month23.70%
Income-140.73M PEG- EPS next Q-0.48 Inst Own89.10% Short Float3.91% Perf Quarter126.69%
Sales0.00M P/S- EPS this Y26.74% Inst Trans12.48% Short Ratio2.37 Perf Half Y92.23%
Book/sh2.95 P/B1.93 EPS next Y3.74% ROA-54.49% Short Interest2.42M Perf Year5.27%
Cash/sh2.11 P/C2.70 EPS next 5Y38.60% ROE-67.42% 52W Range1.57 - 6.67 Perf YTD25.33%
Dividend Est.- P/FCF- EPS past 5Y-39.49% ROI-75.40% 52W High-14.69% Beta1.07
Dividend TTM- Quick Ratio9.85 Sales past 5Y0.00% Gross Margin- 52W Low262.42% ATR (14)0.45
Dividend Ex-Date- Current Ratio9.85 EPS Y/Y TTM43.55% Oper. Margin0.00% RSI (14)64.28 Volatility10.37% 9.72%
Employees80 Debt/Eq0.20 Sales Y/Y TTM- Profit Margin- Recom1.29 Target Price14.00
Option/ShortYes / Yes LT Debt/Eq0.19 EPS Q/Q15.57% Payout- Rel Volume0.46 Prev Close5.25
Sales Surprise- EPS Surprise14.38% Sales Q/Q- EarningsNov 13 BMO Avg Volume1.02M Price5.69
SMA2015.36% SMA5029.05% SMA20070.11% Trades Volume34,527 Change8.38%
Date Action Analyst Rating Change Price Target Change
Dec-21-23Upgrade BofA Securities Neutral → Buy $4 → $6
Oct-30-23Initiated Wells Fargo Overweight $11
May-26-23Downgrade BofA Securities Buy → Neutral $8 → $3
May-25-23Downgrade JP Morgan Overweight → Neutral $19 → $9
Sep-16-22Initiated Jefferies Buy $12
Sep-09-22Initiated BTIG Research Buy $15
Nov-30-21Initiated H.C. Wainwright Buy $40
Sep-23-21Initiated Cantor Fitzgerald Overweight $40
Jan-26-21Initiated Needham Buy $37
Aug-18-20Initiated JP Morgan Overweight $33
Feb-21-24 08:00AM
Feb-20-24 04:05PM
Feb-13-24 01:10PM
Jan-18-24 09:40AM
Jan-17-24 11:06AM
08:00PM Loading…
Jan-07-24 08:00PM
Dec-27-23 06:30AM
Dec-20-23 05:27PM
Dec-18-23 04:01PM
Nov-22-23 04:01PM
Nov-14-23 07:20PM
Nov-13-23 06:30AM
Nov-09-23 06:30AM
06:30AM Loading…
Oct-24-23 06:30AM
Oct-18-23 04:01PM
Oct-10-23 06:30AM
Sep-19-23 06:30AM
Sep-18-23 04:01PM
Sep-08-23 09:35AM
Aug-07-23 06:30AM
Aug-02-23 04:01PM
Jul-30-23 12:00PM
Jul-27-23 06:30AM
Jul-24-23 06:30AM
Jun-14-23 08:36AM
May-30-23 10:40AM
May-26-23 03:05AM
May-25-23 11:52AM
10:12AM Loading…
May-24-23 04:01PM
May-16-23 04:01PM
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
Jan-04-23 06:30AM
Dec-01-22 09:55AM
Nov-21-22 06:13AM
Nov-17-22 04:01PM
Nov-15-22 09:55AM
Nov-03-22 06:30AM
Oct-18-22 04:01PM
Oct-11-22 07:01AM
Sep-16-22 04:01PM
Sep-01-22 05:56PM
Aug-17-22 04:05PM
Aug-08-22 04:01PM
Jul-11-22 06:25PM
Jul-08-22 07:00AM
Jun-07-22 12:19PM
Jun-02-22 06:30AM
Jun-01-22 07:30AM
May-09-22 04:01PM
May-05-22 06:30AM
Apr-21-22 06:02AM
Apr-18-22 10:35AM
Apr-07-22 06:30AM
Apr-04-22 06:30AM
Mar-03-22 04:01PM
Mar-01-22 04:01PM
Feb-28-22 06:30AM
Jan-20-22 06:30AM
Jan-05-22 05:10PM
Jan-04-22 04:05PM
Dec-31-21 08:30AM
Dec-13-21 09:00AM
Nov-30-21 05:24AM
Nov-28-21 11:17AM
Nov-09-21 04:01PM
Oct-19-21 06:38AM
Oct-04-21 10:49AM
Sep-23-21 06:30AM
Sep-20-21 06:30AM
Sep-16-21 11:30AM
Aug-16-21 04:01PM
Jul-22-21 07:00AM
May-21-21 06:30AM
May-17-21 04:05PM
May-05-21 07:00AM
Apr-22-21 01:47AM
Mar-25-21 07:00AM
Mar-01-21 01:11PM
Feb-08-21 07:00AM
Jan-12-21 07:00AM
Jan-05-21 07:00AM
Dec-21-20 07:00AM
Dec-11-20 01:15PM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 20Sale5.512,60414,34872,471Feb 21 04:31 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 20Sale5.532,59314,33982,058Feb 21 04:31 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 20Sale5.481,95110,69185,641Feb 21 04:31 PM
Love DouglasPRESIDENT AND CEOFeb 12Sale5.545,78232,032196,121Feb 14 07:56 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 12Sale5.541,81010,02736,075Feb 14 07:52 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 12Sale5.541,80910,02245,651Feb 14 07:54 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 12Sale5.531,3497,46048,592Feb 14 07:59 PM
Yednock TedEVP & Chief Innovation OfficerDec 27Option Exercise1.6321,00034,17621,000Dec 29 04:12 PM
Yednock TedEVP & Chief Innovation OfficerDec 27Sale4.5221,00094,9660Dec 29 04:12 PM
Satter Muneer ADirectorDec 26Buy2.88350,0001,008,0007,406,024Dec 28 04:30 PM
Lew JenniferEVP & Chief Financial OfficerJul 11Sale3.841,0574,05547,460Jan 23 04:57 PM
Overdorf MichaelEVP & Chief Business OfficerJul 11Sale3.849783,75245,802Jan 23 04:58 PM
Bain Capital Life Sciences Inv10% OwnerMay 25Buy2.13300,000639,7205,701,926May 30 09:54 PM
Last Close
Feb 26 09:40AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.96 Insider Own49.70% Shs Outstand27.43M Perf Week-1.98%
Market Cap16.49M Forward P/E- EPS next Y-2.63 Insider Trans-0.04% Shs Float13.85M Perf Month-6.42%
Income-81.22M PEG- EPS next Q-0.71 Inst Own15.41% Short Float0.01% Perf Quarter-46.05%
Sales0.00M P/S- EPS this Y11.41% Inst Trans-5.85% Short Ratio0.01 Perf Half Y-79.20%
Book/sh1.91 P/B0.31 EPS next Y7.62% ROA-69.04% Short Interest0.00M Perf Year-83.55%
Cash/sh2.17 P/C0.28 EPS next 5Y- ROE-90.85% 52W Range0.49 - 3.98 Perf YTD8.89%
Dividend Est.- P/FCF- EPS past 5Y- ROI-133.33% 52W High-84.95% Beta-0.38
Dividend TTM- Quick Ratio3.81 Sales past 5Y0.00% Gross Margin- 52W Low22.22% ATR (14)0.08
Dividend Ex-Date- Current Ratio3.81 EPS Y/Y TTM5.23% Oper. Margin0.00% RSI (14)44.89 Volatility10.71% 12.44%
Employees89 Debt/Eq0.27 Sales Y/Y TTM- Profit Margin- Recom1.25 Target Price8.00
Option/ShortNo / Yes LT Debt/Eq0.16 EPS Q/Q15.76% Payout- Rel Volume0.89 Prev Close0.58
Sales Surprise- EPS Surprise24.46% Sales Q/Q- EarningsNov 09 AMC Avg Volume188.51K Price0.60
SMA20-3.76% SMA50-8.48% SMA200-69.33% Trades Volume12,467 Change2.89%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
Nov-03-23 12:00PM
09:15AM Loading…
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
Aug-18-23 04:27AM
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
04:05PM Loading…
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
07:30AM Loading…
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Atlas Venture Fund XI, L.P.10% OwnerFeb 08Sale0.647334692,019,563Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 08Sale0.64267171734,546Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12Sale0.831,5401,2782,020,296Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12Sale0.83560465734,813Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11Sale0.871,5661,3622,021,836Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11Sale0.87569495735,373Jan 16 06:16 PM